Credit: Rosalind Franklin University Chicago Medical School

How was disease duration defined in the BE HEARD EXT analysis?

Disease duration was calculated from date of HS diagnosis and divided into quartiles, with the shortest quartile including patients diagnosed less than 2.38 years earlier and the longest quartile including patients diagnosed 10.74 years or more earlier.

What was the key efficacy finding at week 96?

Patients in the shortest-duration quartile reached an IHS4-100 response of 46.1% (53/115), compared with 22.8% (23/101) in the longest-duration quartile, with the gap widening at higher response thresholds.

Does earlier bimekizumab treatment improve outcomes in HS?

The post hoc analysis cannot establish causation, but shorter disease duration was consistently associated with higher rates of stringent response, supporting a possible window-of-opportunity effect.

 often wait years between symptom onset and diagnosis, a delay linked to greater structural damage and reduced treatment response.¹ Whether earlier systemic therapy can change this trajectory has remained largely theoretical, since designing a prospective trial around disease duration is impractical. Bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, is approved for moderate to severe HS in adults.²

Raj Chovatiya, MD, PhD, MSCI, is clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. He co-authored a post hoc analysis addressing the earlier-intervention question using existing trial data from the BE HEARD program.

Researchers pooled data from the phase 3 BE HEARD I and BE HEARD II trials of bimekizumab in moderate to severe HS, along with their open-label extension, BE HEARD EXT.³ Patients were stratified by disease duration quartile, with the shortest quartile including those diagnosed less than 2.38 years earlier and the longest quartile including those diagnosed 10.74 years or more earlier.²

By week 96, patients in the shortest-duration quartile reached an IHS4-100 response of 46.1% (53/115), versus 22.8% (23/101) among patients in the longest-duration quartile.² The separation between quartiles widened at each successive response threshold, from IHS4-55 through IHS4-100, and was most pronounced at the strictest benchmarks.² Response rates improved or held steady in both groups between week 48 and week 96, indicating durability rather than an early plateau.²

In the following interview, Chovatiya discusses how the quartile analysis was constructed and what the widening gap in response rates suggests about timing of systemic therapy in HS.

: What did this pooled 2-year analysis set out to examine, and why is disease duration quartile a meaningful way to assess bimekizumab in HS?

At this point, we've seen a lot of different pieces of the overall bimekizumab data package as it relates to HS. But some of the big questions we have in this inflammatory disease are: if we're able to treat earlier, during this hypothetical window of opportunity, can we change the course of disease, or have higher-level outcomes for our patients? It's with this idea that this analysis was undertaken. Of course, it's challenging to design a real study to answer that question, since it might take many years and a large number of patients.

But this was a post hoc analysis trying to take a look at patients who were on medication for about 2 years, the initial 1 year of the pivotal study as well as the initial extension year, and understand what happens if we take patients who've had disease in the shortest quartile versus the longest quartile. We wanted to understand what clinical outcomes and response look like, and whether that gives us insight into whether it's important to treat early.

: Can you share a few details about the trial's overall layout?

 For the actual study, patients were treated with placebo or bimekizumab, and all patients eventually transitioned to bimekizumab. Those who completed year 1, about 48 weeks of BE HEARD I or II, could enroll in the extension and receive open-label treatment with bimekizumab every 2 or 4 weeks, largely based on their HiSCR75/90 achievement. For this analysis, overall disease duration was divided into quartiles: the lowest quartile was about 2.4 years or less of disease, and the highest quartile was about 10.7 years or more. We were looking at patients who'd had disease for a relatively short time, and patients who'd had it for more than a decade.

: What were the key efficacy findings when comparing the lowest and highest duration quartiles?

 Across both quartiles, whether lower or longer disease duration, the drug was effective, and that largely mirrors what's been seen in other analyses, as well as a lot of our real-world experience: bimekizumab is one of our most effective options for a disease like HS. But what was very interesting is when you look at outcome measures like 75%, 90%, and 100% improvement in the HiSCR, or the IHS4 score at those same thresholds, the proportion of patients in the lower quartile achieving these responses was greater than in the higher quartile. As you moved to higher thresholds, which is what we aim for in this disease space, getting patients under much better control, that gap became even more pronounced between patients with lower and higher disease duration.

: Were there notable differences in how quickly or durably patients responded based on prior HS duration?

We're looking at numerical differences here, so it's difficult to parse out whether there are going to be clear statistical differences. On the whole, we can be reassured that whether a patient has had HS for a few years or many years, durability was still strong, and overall effectiveness was generally good across the board.

It was just smaller, slightly increasing numerical differences in overall efficacy when we looked at the higher-threshold endpoints. I don't think the data here is the end-all, be-all for proving this window-of-opportunity concept, but it's some of the most compelling data we have to date from a large clinical trial program supporting the idea that earlier treatment may incrementally improve our ability to achieve high-level outcomes.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546-1549.

Chovatiya R, Alavi A, Miyagawa T, et al. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 

Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48 week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504-2519.

Articles

Delays between hidradenitis suppurativa symptom onset and diagnosis are common and may worsen irreversible damage and blunt therapeutic responsiveness. A pooled post hoc analysis from the BE HEARD I/II phase 3 program plus open-label extension evaluated bimekizumab outcomes across disease-duration quartiles over 96 weeks. Patients with shorter disease duration (<2.38 years) achieved higher stringent responses than those with long-standing disease (≥10.74 years), most notably for IHS4-100 (46.1% vs 22.8%). Responses remained durable through two years.

Pooled 2-year BE HEARD EXT data show shorter disease duration was linked with higher stringent response rates to bimekizumab in HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Q&A: Bimekizumab 2-Year Efficacy by HS Disease Duration, With Raj Chovatiya, MD, PhD

Bimekizumab produced strong, durable responses in hidradenitis suppurativa regardless of disease duration, with only small numerical differences emerging at the highest efficacy thresholds.

The data do not definitively confirm a window-of-opportunity effect but represent some of the most compelling large-trial evidence to date supporting earlier intervention.

Ongoing diagnostic delay, treatment delay, and undertreatment underscore the need for earlier systemic therapy discussions in HS.

Bimekizumab produced durable and generally strong clinical responses in patients with 

 regardless of how long they had lived with the disease, according to Raj Chovatiya, MD, PhD, discussing pooled 2-year data from the BE HEARD I, BE HEARD II, and BE HEARD EXT trials.

Chovatiya, founder and director of the Center for Medical Dermatology + Immunology Research and associate professor at Rosalind Franklin University Chicago Medical School, noted the differences observed between disease duration quartiles were numerical rather than clearly statistically significant, with durability and overall effectiveness remaining strong across both groups. Small but increasing differences emerged only at the highest-threshold efficacy endpoints.

Bimekizumab Data Support Case for Earlier Intervention in HS

What Does Response Durability Look Like Across Disease Duration?

Patients maintained strong treatment durability whether their HS had been present for a few years or more than a decade, according to Chovatiya. He noted the analysis does not definitively establish a window-of-opportunity effect but represents some of the most compelling large clinical trial evidence to date supporting earlier intervention as a means of incrementally improving high-level outcomes.

What Are the Clinical Implications for Treatment Timing?

Chovatiya said clinicians should not assume advanced-stage HS precludes meaningful benefit from systemic therapy, noting efficacy was achieved with bimekizumab regardless of disease duration. He recommended engaging patients in systemic therapy discussions early after diagnosis rather than delaying treatment.

He pointed to ongoing unmet needs, including diagnostic delay, treatment delay, and variability in severity grading, all of which contribute to undertreatment of HS. Looking ahead, Chovatiya expressed hope that future research will help identify predictive factors, including disease duration, severity, and sociodemographic variables, to guide both treatment selection and timing of intervention.

Disclosures: Chovatiya previously reported serving as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Chovatiya R, Alavi A, Miyagawa T. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 

Chovatiya R. Bimekizumab efficacy by disease duration and severity in moderate to severe hidradenitis suppurativa: 3-year phase 3 results from BE HEARD EXT. 2026. AAD. #73498.

Videos

Raj Chovatiya, MD, PhD, discusses why bimekizumab response durability in HS held steady regardless of disease duration, and what it means for care.

Karen Alexander, MD, is a professor of medicine at Duke University Medical Center.

A new statement from the American College of Cardiology (ACC) aims to evaluate the intersection between cognitive impairment, frailty, and 

 later in life to provide practical approaches to care in an aging population.

ACC Statement Examines Frailty, Cognitive Impairment in Older Patients in Cardiac Settings

Roughly 1 in 3 patients seen in cardiology clinics have some level of cognitive impairment. Frailty affects nearly 50% of community-dwelling older adults and 2 in 3 of older adults undergoing percutaneous coronary intervention. Given the significant proportion of patients experiencing these issues, as well as the growing prevalence of older adults in clinic, the ACC came together to more properly define methods for cardiovascular care among this underrepresented population.

“A lot of the guidelines that come out are focused specifically on the evidence for treatment, and there are gaps where we realize that the patients that we see, and the situations we deal with as clinicians, can be broader than what is able to be addressed by these guidelines,” Karen Alexander, MD, professor of medicine at Duke University Medical Center and chair of the statement’s writing committee, told 

 in an exclusive interview. “That’s exactly the case for this statement, which is really helping to bring forward this population that we treat and figuring out what we need to be doing to treat them as well as we possibly can.”

The risk factors for cognitive impairment and cardiovascular disease are intrinsically intertwined. Both cardiovascular disease risk and cognitive impairment risk increase dramatically with age. Inflammation is also a major player in both conditions, as it contributes directly to plaque instability, thrombosis, and endothelial dysfunction in the cardiovascular system and can produce inflammatory cytokines, which can pass through the blood-brain barrier and trigger neuroinflammation to accelerate cognitive decline. Given this natural association with aging, the ACC statement suggests that cardiovascular disease in older adults should be interpreted in the broader context of biological aging.

Additionally, the team suggests clinicians implement a degree of screening for cognitive impairment and frailty in outpatient settings, primarily focusing on Alzheimer’s disease and dementia. However, the document also notes the challenges inherent in such an approach, such as many patients being unaware of their impairment and appearing superficially normal. The inherent high volume of most primary care clinics is also a substantial barrier to this process. To combat this, Alexander and colleagues recommend simpler screening strategies, such as questionnaires or assessments.

Alexander and colleagues also note the need for further research into several aspects of these recommendations. Prior trials, upon which many of these suggestions were based, have predominantly examined individual ethnic or socioeconomic groups, rendering the data more difficult to extrapolate to other populations. Additionally, the aforementioned high-volume clinics typically facing these issues need more effective screening methods for these cognitive issues, which further studies may be able to provide.

“For so many of us who are seeing these situations in practice and are trying to assemble an approach, the reality is that it’s very hard to get this done because we’re on the clock and we have to see a lot of people,” Alexander said. “Getting it into our training pathways in fellowship would be great – the geriatric toolset 101 for the cardiology fellow. That would be a great start.”

Editors’ Note: Alexander reports no relevant disclosures.

American College of Cardiology. Cardiovascular care for older adults should account for cognitive impairment and frailty. 

 August 10, 2026. Accessed August 14, 2026. 

https://www.eurekalert.org/news-releases/1138835

Alexander K, Damluji A, Erqou S. et al. Cognitive Impairment and Frailty in Older Adults With Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. 

. null2026, 0 (0). August 10, 2026. Accessed August 14, 2026. 

https://doi.org/10.1016/j.jacc.2026.07.009

Karen Alexander, MD, discusses the recent statement evaluating the interconnected relationship between biological aging and cardiovascular risk.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

ACC Statement Examines Frailty, Cognitive Impairment, in Cardiovascular Disease

Dana Rizk, MD, is a professor of medicine in the division of nephrology at the University of Alabama at Birmingham.

Hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, welcome Dana Rizk, MD, professor of medicine in the Division of Nephrology at the University of Alabama at Birmingham. Rizk walks through the 24-month eGFR and safety findings from the phase 3 VISIONARY trial of sibeprenlimab (Voyxact) in 

She presented the late-breaking results at GlomCon Hawaii 2026, building on the proteinuria data reported earlier this year at the European Renal Association meeting. The conversation covers trial design, the eGFR slope and change-from-baseline outcomes, subgroup consistency, safety, and where residual proteinuria fits into the picture going forward.

Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy

VISIONARY Trial Design and 2-Year eGFR Results in Sibeprenlimab-Treated IgAN

Wadhwani opens by asking Rizk to set the scene, noting VISIONARY enrolled 510 patients with biopsy-proven, high-risk IgAN, making it the largest phase 3 trial in the disease to date. Rizk describes the eligibility criteria, an eGFR > 30, a recent biopsy for patients on the lower end, and significant proteinuria of ≥ 1 g/day. Patients were randomized to sibeprenlimab 400 mg subcutaneously every 4 weeks or placebo, on top of maximum tolerated RAS inhibition. 

Rizk explains sibeprenlimab targets APRIL, a cytokine driving B cells to become IgA-secreting within the four-hit model of IgAN pathogenesis, and Wadhwani calls the mechanism one of the most exciting new directions in the field.

Neuen reminds listeners the earlier phase 2 signal was compelling but short, often under a year, and asks Rizk for the full picture now the trial has matured. Rizk reports an annualized eGFR slope of 0.3 mL/min/1.73 m² per year with sibeprenlimab against a placebo decline of 4.2, a 4.5 mL/min/1.73 m² per year treatment difference. Mean eGFR change from baseline told a similar story, with a 9.2 mL/min gap between arms at 2 years. Rizk calls the result striking against the 2025 KDIGO goal of holding eGFR loss < 1 mL/min per year, a bar she once doubted was achievable within a 2-year window.

Consistent Subgroup Benefit and Reassuring Safety Data From VISIONARY

Rizk noted a trio of prespecified subgroups, defined by proteinuria level, baseline eGFR, and SGLT2 inhibitor use, all favored sibeprenlimab with no meaningful difference in effect size across strata. Neuen called the consistent benefit in SGLT2 inhibitor users reassuring for clinicians considering combination therapy for long-term kidney preservation.

On safety, Neuen names the theoretical concern hanging over any B-cell modulating agent: infection risk from suppressing immune function. Rizk reports adverse events in about 90% of both arms, with treatment-related events similar between groups and serious infections less common with sibeprenlimab than placebo. No deaths occurred, and discontinuation for adverse events stayed in the low single digits. Wadhwani follows up on immunoglobulin monitoring, and Rizk notes patients needed an IgG level > 600 at entry, with full IgA, IgG, and IgM data still to come.

Residual Proteinuria and the Road Ahead for B-Cell Therapy in IgAN

With median proteinuria still > 0.5 gram/day despite the 51% reduction, Wadhwani raised concern about residual proteinuria as a cardiovascular risk factor independent of stabilized eGFR. She compared it to how cardiologists treat persistent albuminuria. Rizk agreed proteinuria cannot distinguish ongoing immunologic activity from fixed scarring, and said mechanistic studies pairing biopsies before and after treatment should help clarify the distinction. 

The conversation closes on biomarkers, with Wadhwani asking whether galactose-deficient IgA1 can separate disease activity from fibrosis on its own. Rizk says the field has been spoiled by the PLA2R antibody in membranous nephropathy and expects IgAN will need a panel of biomarkers rather than one perfect test. She points to pediatric IgAN, membranous nephropathy, lupus nephritis, and IgA vasculitis as likely next frontiers for anti-APRIL therapy. 

Wadhwani adds trials still struggle to capture good hematuria data given how urine samples are collected. Rizk says post hoc analyses are planned for patients enrolled with lower baseline proteinuria, thanking the patients and investigators who carried VISIONARY through its multi-year follow-up.

Wadhwani closes by reflecting on how far the field has moved. A decade ago, clinicians reserved corticosteroids for patients with more than a gram of proteinuria after months of failed RAS inhibition, often leaving patients undertreated given the steroid burden. She contrasts this with a once-monthly injection appearing well tolerated and capable of stabilizing kidney function outright. Rizk also raises a question about whether anti-APRIL therapy has a role preventing IgAN recurrence after kidney transplant, calling it an open area for future study. 

 include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Disclosures for 

 include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. Disclosures for 

 include Novartis Pharmaceuticals, Otsuka Pharmaceutical Inc., Vera Therapeutics, Biogen, Travere Therapeutics, and others.

Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy: interim analysis of a phase 3 trial. 

. 2026;394(7):635-646. doi:10.1056/NEJMoa2512133

Otsuka. Otsuka unveils unprecedented phase 3 VISIONARY two-year eGFR results demonstrating VOYXACT (sibeprenlimab-szsi) stabilizes kidney function decline to baseline physiologic rate, fundamentally altering disease progression in IgA nephropathy (IgAN). News release. August 3, 2026. 

https://www.otsuka-us.com/news/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrating-voyxactr

Rizk DV, Perkovic V, Trimarchi H, et al. Two-year eGFR and safety results from the VISIONARY phase 3 trial of sibeprenlimab in IgA nephropathy. Presented at: GlomCon Hawaii; August 3-7, 2026; Maui, HI.

Podcasts

Dana Rizk, MD, joins hosts Brendon Neuen and Shikha Wadhwani to unpack 2-year VISIONARY data showing sibeprenlimab stabilizes eGFR in IgAN.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Kriti Puri, MBBS, is a pediatric cardiologist and cardiac intensive care physician with Texas Children’s Hospital and an assistant professor at the Baylor College of Medicine.

A new proposed definition of cardiogenic shock in pediatric patients may pave the way for improved intervention and outcomes for this notoriously underrepresented condition.

Recognizing, Diagnosing, and Managing Pediatric Cardiogenic Shock

Despite being heavily studied in adult patients, there is still very little evidence regarding cardiogenic shock in pediatric patients. A 2023 study published in the Journal of the American College of Cardiology investigated the incidence, epidemiology, and outcomes of cardiogenic shock in pediatric patients – this study found that the disease occurs in roughly 26% of pediatric hospitalizations for 

 and is independently associated with hospital mortality.

To address this issue, Kriti Puri, MBBS, a pediatric cardiologist and cardiac intensive care physician with Texas Children’s Hospital and an assistant professor at the Baylor College of Medicine, and colleagues proposed a new definition for the disease in pediatric patients, as well as providing suggestions on each step of the treatment process for this underrepresented condition.

“The definition that we propose in this statement basically just encourages clinicians to think of the heart, especially if they have a patient that is in undifferentiated shock without prior known cardiac history,” Puri told 

 in an exclusive interview. “And then if there is that suspected cardiac dysfunction, and they have evidence of hypoperfusion, clinicians should really consider it as cardiogenic shock unless proven otherwise and utilize those principles of management.”

Puri and colleagues searched the limited existing literature regarding pediatric cardiogenic shock, collating existing data into the current document. The team noted that this literature is intrinsically limited by small sample sizes and selection bias. Larger cohort studies typically examined patients with ADHF – these documents may not always distinguish between patients with early or beginning cardiogenic shock and those with more extreme severity, potentially leading to invasive circulatory or respiratory support.

From the existing data, Puri and colleagues developed a classification system for cardiogenic shock, constructed similarly to the Society of Cardiovascular Angiography and Imaging (SCAI) classification for adults. In the present system, patients with known or suspected cardiac dysfunction are considered at risk, while those with evidence of derangement of vital signs or hemodynamics from baseline and symptoms have beginning cardiogenic shock. Patients with evidence of hypoperfusion, with or without hypotension, are in classic cardiogenic shock, while those who have received an intervention but are continuing to worsen are in stage D, or deteriorating, cardiogenic shock. Patients presenting or deteriorating to circulatory collapse requiring resuscitation are in stage E.

Puri and colleagues also established a diagnostic process for cardiogenic shock, including a physical examination for congestion or low cardiac output. The team recommends chest radiographs and electrocardiograms, which provide insight rapidly into the cause of cardiogenic shock. Additionally, near-infrared spectroscopy, when possible, may be useful in evaluating regional capillary-venous hemoglobin saturation.

In regard to monitoring, Puri and colleagues recommend the establishment of durable/central venous access and the placement of an arterial line to monitor adequacy of cardiac output, tissue perfusion, and arterial oxygen content. Additionally, the team suggests central venous oxygen saturation sampling and NIRS.

The authors note that management of pediatric cardiogenic shock should focus on hemodynamic optimization, aiming to restore adequate oxygen delivery to peripheral tissues while minimizing oxygen use. They also point out that initial management often occurs in an emergency department or another noncardiac intensive care setting – to this end, Puri and colleagues indicate that therapy should largely focus on facilitating transfer to a higher level of care.

Ultimately, despite the depth and specificity of the document, Puri and colleagues note the need for further research to further tailor these recommendations. Locating biomarkers of cardiogenic shock, as well as delineating phenotypes and optimizing interventions, are critical next steps for the refinement of this preliminary definition.

“The proposed definition and classification system, while they are new and while we have adapted them from data that have previously shown that they are valid, there is probably room for further finessing,” Puri said. “We are the first to admit that pediatrics still needs a lot of studies on the true phenotypes of pediatric cardiogenic shock, the impact of inflammation, and the impact of socioeconomic determinants of health as a risk modifier. These are the aspects that still need more data.”

Editors’ Note: Puri reports no relevant disclosures.

Puri K, Allen K, Jentzer J, et al. Surviving pediatric cardiogenic shock: Clinical approach, improving outcomes, and future directions: A scientific statement from the American Heart Association. 

Puri K, Jentzer JC, Spinner JA, et al. Clinical presentation, classification, and outcomes of cardiogenic shock in children. Journal of the American College of Cardiology. 2024;83(5):595-608. 

Kriti Puri, MBBS, and colleagues have developed a preliminary definition and treatment strategy for this underrepresented disease.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Pooled 2-year data show bimekizumab drove greater high-threshold HS responses in patients with shorter versus longer disease duration.

BE HEARD EXT: Bimekizumab Shows Greater Benefit With Earlier Use in HS

Ronald D’Agostino, DO, is a cardiologist affiliated with networks such as NYU Langone Health and Catholic Health Long Island.

Ronald D'Agostino, DO, discusses the 2026 HFpEF pathway, H2FPEF screening, and comorbidity-first heart failure care.

Rethinking HFpEF Screening and Care, With Ronald D'Agostino, DO

Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, to describe the patient profile she has in mind when reaching for icotrokinra.

Choosing the Right Plaque Psoriasis Patient for Icotrokinra

Jay Lieberman, MD, from University of Tennessee

Lieberman discusses atypical anaphylaxis signs in infants and toddlers and why epinephrine remains underused.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Q&A: Anaphylaxis Recognition and Epinephrine Use, With Jay Lieberman, MD

The discussion turns to mechanism of action as Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, where icotrokinra sits conceptually relative to the biologic classes that have anchored psoriasis treatment.

Where Oral Peptide Therapy Fits Alongside Biologics in Plaque Psoriasis

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

One year after brensocatib's FDA approval, 2 pulmonologists describe real-world response and a new CHEST guideline.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

One Year of Brensocatib: How Bronchiectasis Care Has Changed

In part 2, Lieberman discusses why caregivers hesitate to use epinephrine and what system-level changes could close the gap in infants and toddlers.

Stock Epinephrine Could Close Anaphylaxis Care Gap, With Jay Lieberman, MD

Tiffany Mayo, MD, discusses the pressure of representation in medical leadership, setting boundaries, and staying authentic as a woman of color.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: The Pressure of Representation, With Tiffany Mayo, MD

Rima Rachid, MD, from Boston Children’s Hospital.

Rima Rachid, MD, discusses the purified MTT formulation, phase 2 trial design, and the gut bacteria driving protection against peanut allergy.

Food Allergy

Q&A: Microbiota Transplantation Therapy Simplifies Dosing for Peanut Allergy

Germline STXBP2 variants may predict severe CAR T cell toxicity, Mark B. Leick, MD, and colleagues find

Latest News

Q&A: Bimekizumab 2-Year Efficacy by HS Disease Duration, With Raj Chovatiya, MD, PhD

Bimekizumab Data Support Case for Earlier Intervention in HS

ACC Statement Examines Frailty, Cognitive Impairment, in Cardiovascular Disease

Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy

Recognizing, Diagnosing, and Managing Pediatric Cardiogenic Shock